SEC Company Response from Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196) (CANF) — Jan 29, 2016
Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)
Date: Jan. 29, 2016 · CIK: 0001536196 · Accession: 0001213900-16-010461
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-209037
Letter
CAN-FITE BIOPHARMA LTD.
10 Bareket Street,
Kiryat Matalon
PO Box 7537
Petach Tikva, 4951778
Israel
January 29, 2016
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Alla Berenshteyn
Re: Can-Fite BioPharma Ltd.
Registration Statement on Form F-3 Filed January 19, 2016
File No. 333-209037
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Can-Fite BioPharma Ltd. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on January 29, 2016, or as soon thereafter as possible.
The Company hereby acknowledges the following:
· should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
· the Company may not assert staff comments and the declaration of effectiveness of this Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
CAN-FITE BIOPHARMA LTD.
By: /s/ Motti Farbstein
Name: Motti Farbstein Title: Chief Operating and Financial Officer
Show Raw Text
CORRESP
1
filename1.htm
CAN-FITE BIOPHARMA LTD.
10 Bareket Street,
Kiryat Matalon
PO Box 7537
Petach Tikva, 4951778
Israel
January 29, 2016
VIA
EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Alla Berenshteyn
Re:
Can-Fite BioPharma Ltd.
Registration Statement on Form F-3 Filed
January 19, 2016
File No. 333-209037
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Can-Fite BioPharma Ltd. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become
effective at 4:30 p.m., Eastern Time, on January 29, 2016, or as soon thereafter as possible.
The
Company hereby acknowledges the following:
· should the Securities and Exchange Commission (the “Commission”) or the staff,
acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from
taking any action with respect to the Registration Statement;
· the action of the Commission or the staff, acting pursuant to delegated authority, in
declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and
accuracy of the disclosure in the Registration Statement; and
· the Company may not assert staff comments and the declaration of effectiveness of this
Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws
of the United States.
CAN-FITE
BIOPHARMA LTD.
By:
/s/ Motti Farbstein
Name: Motti Farbstein
Title: Chief Operating and Financial
Officer